score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.8286	245.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	166.0	0.8795	1.0	BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat08	MEL-IPI_Pat08-Tumor-SM-4DK14	MEL-IPI_Pat08-Normal-SM-4NFUA
Putatively Actionable	Preclinical	Clinical evidence		Copy Number	PTEN	Deletion				0.0	0.0		Putatively Actionable	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Putatively Actionable	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001						0				PTEN Deletion	1.0	MEL-IPI_Pat08	MEL-IPI_Pat08-Tumor-SM-4DK14	
Putatively Actionable	Preclinical		Preclinical	Copy Number	AURKA	Amplification				0.0	0.0		Putatively Actionable	Danusertib	Aurora kinase inhibition	Targeted therapy	Neuroendocrine prostate cancer (NEPC) cell lines shows enhanced sensitivity to pan-Aurora kinase inhibitor therapy, specifically to PHA-739358 (Danusertib).	Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487-95.	https://doi.org/10.1158/2159-8290.CD-11-0130								Putatively Actionable	0.0	Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth	"Sillars-Hardebol, Anke H., et al. ""TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression."" Gut 61.11 (2012): 1568-1575."	https://doi.org/10.1136/gutjnl-2011-301153	0				AURKA Amplification		MEL-IPI_Pat08	MEL-IPI_Pat08-Tumor-SM-4DK14	
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R337C	0.8111	217.0	9.1e-05	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007													0	349.0	0.8539	1.0	ATM p.R337C (Missense)	1.0	MEL-IPI_Pat08	MEL-IPI_Pat08-Tumor-SM-4DK14	MEL-IPI_Pat08-Normal-SM-4NFUA
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat08		
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.S819F	0.4386	668.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	37.0	0.5135	1.0	BRCA1 p.S819F (Missense)	1.0	MEL-IPI_Pat08	MEL-IPI_Pat08-Tumor-SM-4DK14	MEL-IPI_Pat08-Normal-SM-4NFUA
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.L152I	0.8706	85.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf													0	74.0	0.7432	1.0	TSC1 p.L152I (Missense)		MEL-IPI_Pat08	MEL-IPI_Pat08-Tumor-SM-4DK14	MEL-IPI_Pat08-Normal-SM-4NFUA
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E740Q	0.3885	157.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098													0	456.0	0.4101	1.0	SMARCA4 p.E740Q (Missense)		MEL-IPI_Pat08	MEL-IPI_Pat08-Tumor-SM-4DK14	MEL-IPI_Pat08-Normal-SM-4NFUA
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R7*	0.7407	27.0	0.0	0.0																					0	0.0	0.0	0.0	CDKN2A p.R7* (Nonsense)		MEL-IPI_Pat08	MEL-IPI_Pat08-Tumor-SM-4DK14	MEL-IPI_Pat08-Normal-SM-4NFUA
Biologically Relevant				Copy Number	TMPRSS2	Amplification				0.0	0.0																					0				TMPRSS2 Amplification		MEL-IPI_Pat08	MEL-IPI_Pat08-Tumor-SM-4DK14	
Biologically Relevant				Copy Number	ESRP1	Amplification				0.0	0.0																					0				ESRP1 Amplification		MEL-IPI_Pat08	MEL-IPI_Pat08-Tumor-SM-4DK14	
Biologically Relevant				Copy Number	EML4	Deletion				0.0	0.0																					0				EML4 Deletion		MEL-IPI_Pat08	MEL-IPI_Pat08-Tumor-SM-4DK14	
Biologically Relevant				Copy Number	JAK2	Deletion				0.0	0.0																					0				JAK2 Deletion		MEL-IPI_Pat08	MEL-IPI_Pat08-Tumor-SM-4DK14	
Biologically Relevant				Copy Number	SETBP1	Deletion				0.0	0.0																					0				SETBP1 Deletion		MEL-IPI_Pat08	MEL-IPI_Pat08-Tumor-SM-4DK14	
Biologically Relevant				Copy Number	ALK	Deletion				0.0	0.0																					0				ALK Deletion		MEL-IPI_Pat08	MEL-IPI_Pat08-Tumor-SM-4DK14	
Biologically Relevant				Microsatellite Stability	Supporting variants		ESRP1 Amplification, PRDM2 p.703_704insP (Insertion), PRDM2 p.E1261del (Deletion)																									0				Supporting variants: ESRP1 Amplification, PRDM2 p.703_704insP (Insertion), PRDM2 p.E1261del (Deletion)		MEL-IPI_Pat08		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.912																									0				COSMIC Signature (version 2) 7 (91%)		MEL-IPI_Pat08		
